These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36049756)

  • 41. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Krogh J; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis.
    Chen C; Peng H; Li M; Lu X; Huang M; Zeng Y; Dong G
    Front Endocrinol (Lausanne); 2021; 12():664533. PubMed ID: 34759887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wei R; Wang W; Pan Q; Guo L
    Front Endocrinol (Lausanne); 2022; 13():826604. PubMed ID: 35250882
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis.
    Dorsey-Treviño EG; González-González JG; Alvarez-Villalobos N; González-Nava V; Contreras-Garza BM; Díaz González-Colmenero A; Rodríguez-Tamez G; Barrera-Flores FJ; Farrell AM; Montori VM; Rodriguez-Gutierrez R
    J Endocrinol Invest; 2020 Mar; 43(3):289-304. PubMed ID: 31489568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
    Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
    Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
    Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.
    Huang Y; Jiang Z; Wei Y
    Endokrynol Pol; 2020; 71(4):325-333. PubMed ID: 32901912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta-analysis.
    Chen MB; Wang H; Cui WY; Xu HL; Zheng QH
    Medicine (Baltimore); 2021 Feb; 100(6):e24593. PubMed ID: 33578559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Xia C; Han Y; Yin C; Geng R; Liu Z; Du Y; Yu M
    Front Endocrinol (Lausanne); 2023; 14():1220516. PubMed ID: 37780608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
    Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.